AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

In a second setback for glioblastoma multiforme patients this month, AbbVie said its depatuxizumab mafodotin missed the primary endpoint of improving overall survival in the Phase III INTELLANCE-1 for newly diagnosed EGFR-amplified GBM.

AbbVie Inc. (NYSE:ABBV) management had touted its

Read the full 398 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE